Discover the

future

of biotech

Your best source for early-stage biotech signals

PERSONALIZED BIOTECH INTELLIGENCE

Stop reading biotech news that isn't relevant to you

Make a profile. Tell us your role, your therapeutic areas, and the companies you’re watching. We’ll deliver a personalized briefing with only the signals that matter to your work.

🔥HOT SIGNALS

April 29, 2026

TDP-43 Finally Has a Real Toolbox: Two ALS Programs, Two Modalities, One Protein

Two ALS programs, two modalities, one protein. AcuraStem's ASO and VectorY's vectorized antibody are starting to give the 97% of ALS patients without SOD1 mutations a real toolbox.

April 29, 2026

Tacalyx Lands €11M to Take Glycan-Targeted ADCs Out of the Curiosity Bin

Tacalyx pulls €11M seed extension to push glycan-targeted ADC TCX-201 toward 2027 CTA filing.

PERSONALIZED BIOTECH INTELLIGENCE

Stop reading biotech news that isn't relevant to you

Make a profile. Tell us your role, your therapeutic areas, and the companies you’re watching. We’ll deliver a personalized briefing with only the signals that matter to your work.

📰 RECENT ARTICLES

April 30, 2026

Tempest Pivoted Into CAR-T And The Early Data Looks Good

April 29, 2026

TDP-43 Finally Has a Real Toolbox: Two ALS Programs, Two Modalities, One Protein

April 29, 2026

Tacalyx Lands €11M to Take Glycan-Targeted ADCs Out of the Curiosity Bin

April 29, 2026

Hypervision Surgical’s £17M Round Bets on AI in the OR, Not the Lab

April 29, 2026

Theolytics Doses First Ovarian Patient with a Virus That Kills Both Tumor and Stroma

PERSONALIZED INTELLIGENCE

Get your own bi-weekly briefing.
For free.

Tell us your role, your therapeutic areas, and the companies you’re watching. We’ll deliver a briefing with only the signals that matter to your work — ranked, contextualized, and written for you.

Powered by HOUSTON | FLYTE Bio Intelligence Platform

INTELLIGENCE REPORTS

Landscape Reports

Deep-dive intelligence reports mapping the companies shaping biotech’s next chapter.

Powered by HOUSTON | FLYTE Bio Intelligence Platform

AI In Biotech

How will AI change biotech in the next 3-5 years

View All

ViewsML Raises $4.8M Seed With Plans To Replace Tissue Staining With AI.

AI In Biotech

ViewsML closed a $4.9M seed for AI virtual biomarker staining from standard pathology images.

Novo Nordisk Called OpenAI. So Did Everyone Else.

AI In Biotech

Novo Nordisk partners with OpenAI as AI drug discovery deal flow surpasses $5B in five months.

One Bought a Podcast. The Other Bought a Lab.

AI In Biotech

Anthropic dropped $400M on a 9-person biotech AI startup. The same day, OpenAI bought a podcast. That tells you everything.

$787 Million Says AI Can Design Better Biologics Than You

AI In Biotech

An AI-native biologics company just raised $787M with Sanofi and a Pfizer/Hillhouse fund backing it — and they already have a Phase 2 asset.

EMERGING MODALITIES

Tracking the next therapeutic wave before it breaks

View All

Immunofoco Already Has a Phase 3 CAR-T. Now It’s Making Them Inside the Patient.

Emerging Modalities

Immunofoco presented preclinical data for IMV102, an in vivo BCMA CAR-T built on its iMAGIC lentiviral platform.

EpiBiologics Is Taking Extracellular Protein Degradation Into The Clinic

Emerging Modalities

EpiBiologics dosed the first patient with EPI-326, a bispecific antibody degrader hitting wild-type and mutant EGFR.

Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.

Emerging Modalities

Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.

An Auger-Emitting Radioconjugate for Triple-Negative Breast Cancer

Emerging Modalities

Cellectar Biosciences enrolls first patient in Phase 1b of CLR 125, an iodine-125 Auger emitter targeting refractory TNBC.

COMPANY PROFILES

The companies shaping the future of biotech

View All

Deck Bio

April 9, 2026

Multi-target T cell engagers redirecting immunity against intracellular cancer antigens in solid tumors.

Ternary Therapeutics

April 6, 2026

AI-driven platform designing molecular glue therapeutics for undruggable targets in immunology and neuroinflammation.

Stipple Bio

April 6, 2026

Epitope-resolution platform discovering tumor-specific cell surface targets for precision ADCs and next-generation oncology therapeutics.

TRIANA Biomedicines

April 4, 2026

Rational molecular glue degrader platform targeting undruggable oncology targets, with lead ALK fusion degrader in Phase 1/2 for NSCLC.